Rigel Pharmaceuticals (NASDAQ:RIGL) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.
Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Beyond ITP, the company is advancing clinical programs of fostamatinib in other immune-mediated conditions, including IgA nephropathy, and is exploring additional indications where modulation of SYK and related kinases may provide therapeutic benefit.
In addition to its late-stage asset, Rigel maintains a preclinical pipeline of small molecule inhibitors directed against kinases such as RIP1, BTK and other targets implicated in inflammation, anemia and fibrotic diseases. The company’s research efforts are supported by strategic collaborations and licensing agreements, enabling access to complementary expertise and resources for clinical development and potential commercialization in key markets across North America and Europe.
Guided by a leadership team with extensive experience in drug discovery and development, Rigel Pharmaceuticals remains committed to advancing innovative therapies that can improve patient outcomes. The company continues to engage with regulatory authorities, academic institutions and patient advocacy groups to facilitate the translation of its scientific programs from bench to bedside.
